Alzamend Neuro, Inc. financial data

Symbol
ALZN on Nasdaq
Location
3500 Lenox Rd. Ne, Suite 1500, Atlanta, GA
State of incorporation
Delaware
Fiscal year end
April 30
Latest financial report
10-Q - Q2 2024 - Sep 11, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 449 % -64.7%
Debt-to-equity -133 % -337%
Return On Equity 275 %
Return On Assets -727 % -225%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.89M shares -96%
Common Stock, Shares, Outstanding 861K shares -99.1%
Entity Public Float 6.7M USD -89.9%
Common Stock, Value, Issued 86 USD -99.1%
Weighted Average Number of Shares Outstanding, Basic 778K shares +18.5%
Weighted Average Number of Shares Outstanding, Diluted 778K shares +18.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.3M USD -49.1%
General and Administrative Expense 3.08M USD -55.5%
Costs and Expenses 14.9M USD +20.7%
Operating Income (Loss) -7.37M USD +52%
Nonoperating Income (Expense) -20.3K USD -153%
Net Income (Loss) Attributable to Parent -7.39M USD +51.9%
Earnings Per Share, Basic -10.6 USD/shares +62.6%
Earnings Per Share, Diluted -10.6 USD/shares +62.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.19M USD -29.6%
Assets, Current 1.42M USD -41.3%
Property, Plant and Equipment, Net 254K USD +18.3%
Assets 1.67M USD -36.5%
Accounts Payable, Current 2.88M USD +5.16%
Liabilities, Current 3.83M USD +44.8%
Liabilities 2.88M USD +5.16%
Retained Earnings (Accumulated Deficit) -55M USD -15.5%
Stockholders' Equity Attributable to Parent -1.21M USD -974%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -1.21M USD -974%
Liabilities and Equity 1.67M USD -36.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.06M USD +68%
Net Cash Provided by (Used in) Financing Activities 1.96M USD
Net Cash Provided by (Used in) Investing Activities -90K USD +38.9%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 861K shares -99.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.19M USD -29.6%
Deferred Tax Assets, Valuation Allowance 15.8M USD +45.8%
Deferred Tax Assets, Gross 15.8M USD +45.9%
Depreciation 12.7K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 10.8M USD +57.4%
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 53.8M USD -13.8%
Share-based Payment Arrangement, Expense 187K USD -87.6%
Interest Expense 20.3K USD +153%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%